web analytics
-0.8 C
Munich
Saturday, November 26, 2022

Premier Biomedical Inc (OTCMKTS:BIEI) Reverse Merger Candidate Getting Noticed as Co Files Attorneys Letter and Looks to Go Pink Current

Premier Biomedical Inc (OTCMKTS:BIEI) is moving steadily northbound in recent trading as reverse merger rumors continue to abound. The Company is working hard behind the scenes trying to get the Company to “pink current” filing its attorney’s letter on October 6. BIEI is the perfect reverse merger candidate with just $2 million in liabilities, $1.4 million of which is a derivative liability. 

Reverse merger SPACS can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and many RM stocks, we have covered on this website have gone from pennies to dollars. Two recent RM runners that stand out are TSNP/HMBL which went from sub pennies (where we first wrote about it) to several dollars per share. The other is HRBR which went from a few cents (where we first wrote about it) to $3 plus. CNNA is the perfect reverse merger candidate with a clean balance sheet and little debt besides the $3.2 million derivative liability. 


Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Premier Biomedical Inc (OTCMKTS:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.

We last reported on BIEI in April 2020 stating at the time: “Premier Biomedical Inc (OTCMKTS:BIEI) has been on a wild run in recent weeks attracting legions of shareholders and establishing itself as a volume leader in small caps. Investors are accumulating BIEI since the Company is making progress in its pursuit of a cure for severely ill patients suffering from the Coronavirus pandemic. Recently the Company has filed 2 separate provisional patent applications; Method for Treating and Curing Covid-19 Infection, by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical as well as “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients,” by Mitchell S. Felder, M.D., the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical. More recently BIEI signed a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch™ with Gold River Productions Inc. BIEI management team led by William A. Hartman recently stated: “We believe that our extracorporeal approach could cure severely ill Covid-19 infected patients without causing any undesirable side effects, such as “cytokine storm”, via the removal of certain non-structural proteins which the Covid-19 virus needs for replication.” 

To Find out the inside Scoop on BIEI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEI

The last press release from the Company was in May 2020 when they reported an agreement to pursue a novel coronavirus extracorporeal treatment which combines Premier Biomedical’s antigen mapping technique with Datatecnics’ laser ablation technology in a focused “Map and ZapTM” treatment protocol disclosed in a provisional patent application that is intended to eliminate COVID-19 antigens and potential mutations. Research is expected to start this quarter to develop complexing agents to bind with coronavirus antigens which can be illuminated and eliminated using a computer-controlled targeting and laser system. The proposed hospital/clinic process would illuminate the compounded molecular target disease antigens for destruction by a nano-focus laser, and the purified blood would then be returned to the patient. 

Dr. Mitchell Felder, inventor of the patented extracorporeal treatment process (U.S. Patent 9,216,386 and U.S. Patent 8,758,287), indicated, “Our first step in bringing this “Map & Zap™” process to fruition is to develop the biomarkers which can bind to the target coronavirus antigen molecules in the blood. We are very confident, that together with our university partners, we can identify and produce the requisite biomarkers in a relatively short period of time. This process is embodied in the provisional patents entitled: “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.” 

For More on BIEI Subscribe Right Now!

Currently trading at a $1.7 million market valuation BIEI OS is completely maxed out at 999,980,958 (which means they cannot issue any shares and even if a third party had convertible debt, they couldn’t convert it) and just 8.2 million in the public float. BIEI is moving steadily northbound in recent trading as reverse merger rumors continue to abound. The Company is working hard behind the scenes trying to get the Company to “pink current” filing its attorney’s letter on October 6. BIEI is the perfect reverse merger candidate with just $2 million in liabilities, $1.4 million of which is a derivative liability.  We will be updating on BIEI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEI.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BIEI either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.